<DOC>
	<DOCNO>NCT00118976</DOCNO>
	<brief_summary>The primary aim evaluate anti proteinuric effect increase dos ACE inhibitor , lisinopril : 20 , 40 60 mg daily type 1 diabetic patient hypertension diabetic nephropathy . The secondary aim evaluate effect blood pressure ( 24 hour ambulatory blood pressure ) kidney function ( glomerular filtration rate ( GFR ) ) . The tertiary aim evaluate difference response treatment accord ACE/insertion/deletion ( ID ) -genotypes genetic variant gene renin angiotensin system .</brief_summary>
	<brief_title>Maximal Dose Angiotensin Converting Enzyme ( ACE ) Inhibitor Treatment Diabetic Kidney Disease</brief_title>
	<detailed_description>This randomize , double-blind cross-over study three treatment period consist 20 , 40 60 mg lisinopril daily random order . The endpoint study examined treatment period . There wash treatment period . To minimize risk hypotension every treatment period start 20 mg lisinopril two week . Thus , risk adverse effect minimize increase dose 0 mg 60 mg lisinopril avoid . The patient usual antihypertensive treatment stop period 8 week ( wash ) randomization . Since diuretic drug need almost every patient study avoid oedema patient treat lasix retard 60 – 120 mg daily . Patients : 60 type 1 diabetic patient diabetic nephropathy hypertension ( blood pressure &gt; 135 mm Hg systolic and/or 85 mm Hg diastolic ) . Methods : The endpoint study examine baseline treatment period correspond 8 , 16 , 24 week randomization . The following parameter determine treatment period : Albuminuria ( determine three consecutive 24 hour urine collection ) , kidney function ( GFR – plasma clearance 51Cr-EDTA ) , 24 hour ambulatory blood pressure ( TM-2420/2421 ) . Furthermore , concentration TGF-ß , sodium , creatinine , carbamide 24 hour urinary sample determine . The plasma concentration albumin , renin , angiotensin II , aldosterone measure . DNA extract blood sample genetic variant renin-angiotensin system measure include ACE/ID genotype . Endpoints : Primary endpoint : albuminuria ; Secondary endpoint : blood pressure ( 24 hour ambulatory ) GFR ; Tertiary : difference response treatment patient different ACE/ID renin angiotensin system genotype .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>Type 1 diabetes ( WHO criteria ) Diabetic nephropathy ( 2 3 consecutive 24 hour urinary sample albumin excretion &gt; 300 mg/24hour diabetic retinopathy absence sign kidney urinary tract disease ) 27 diabetic glomerulosclerosis verify biopsy . Hypertension : Blood pressure &gt; 135 mmHg systolic and/or 85 mm Hg diastolic repeatedly . Age 18 70 year . Age &lt; 18 year &gt; 70 year . Pregnancy fertile woman use adequate anticonceptive ( intrauterine device , sterilization , oral anticonceptive ) Malignant hypertension . Blood pressure &gt; 180/105 mm Hg Known renal artery stenosis GFR &lt; 30 ml/min/1.73 m² Serum potassium &gt; 4.8 mmol/ l Heart failure , myocardial infarction , unstable angina coronary bypass operation within previous three month . Abuse drug alcohol . Not able understand write information . Known intolerance ACE inhibitor . Chronic use non steroid inflammatory drug aspirin ( 1 g/day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>diabetic nephropathy</keyword>
	<keyword>type 1 diabetes</keyword>
	<keyword>albuminuria</keyword>
	<keyword>hypertension</keyword>
</DOC>